5-trimethylstannyl-pyrimidine | 69849-42-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-trimethylstannyl-pyrimidine
• 英文别名: trimethyl-5-pyrimidylstannane；5-pyrimidyl(trimethyl)tin；5-trimethylstannyl-3,5-pyrimidine；5-trimethyltinpyrimidine；trimethyl(pyrimidin-5-yl)stannane
• CAS: 69849-42-9
• 化学式: C₇H₁₂N₂Sn
• 分子量: 242.896
• InChiKey: CCXFZGWHOYXGHW-UHFFFAOYSA-N

物化性质

• 沸点：
  229.8±32.0 °C(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.02
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3,5-三溴苯 、 5-trimethylstannyl-pyrimidine 在 bis-triphenylphosphine-palladium(II) chloride 、 lithium chloride 作用下， 以 甲苯 为溶剂， 反应 12.0h， 以41%的产率得到3,5-dibromo-1-(3,5-pyrimidyl)benzene
  参考文献：
  名称：

  通过协调实现分子嵌板：八种金属和四种配体的开锥和四面体结构的客控组装

  摘要：

  DOI：

  10.1021/ja001411i
• 作为产物：
  描述：

  5-溴嘧啶 、 三甲基氯化锡 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 3.5h， 以50%的产率得到5-trimethylstannyl-pyrimidine
  参考文献：
  名称：

  共轭单体和在主链中包含 2,5-连接恶唑的聚合物的途径

  摘要：

  探索了将咪唑、嘧啶和恶唑连接到其他共轭核心单元，以寻求产生单体以合成有机半导体聚合物。区域规则的恶唑侧翼噻吩、苯并噻二唑、萘二亚胺 (NDI) 和噻吩并吡咯二酮 (TPD) 通过恶唑的单烷基化和溴化核心单元的 Stille 偶联成功分离（总收率范围为 40% 至 60%）。通过随后的直接芳基化聚合，获得了在半导体状态下具有光学和电化学轨道能量学的含有 NDI/恶唑/TPD 的区域异构聚合物。

  DOI：

  10.1021/acs.joc.2c00511

文献信息

• Pyrazinyl-substituted naphthalene derivatives
  申请人：——

  公开号：US20010004669A1

  公开（公告）日：2001-06-21

  Compounds of the formula 1 where R 1 is of the formulae 2 R 2 is —R 4 , —O—R 4 , —O—S (O) 2 —R 4 , —NR 4 R 5 , R 4 —(CH 2 ) b —NH(C═X)—(CH 2 )—, R 4 —(CH 2 ) b —O(C═O)NH—(CH 2 ) c —(C═O)NH—, R 4 (C═O)NH—(C═O)NH—, —(CH 2 ) b —NH(C═X)—(CH 2 ) c —R 4 , R 4 —(CH 2 ) b —O(C═)—(CH 2 ) c —, —(CH 2 ) b —O(C═O)—(CH 2 ) c —R 4 , —NH(C═X)NH—R 4 , R 4 —O(C═O)O—, —O(C═)NH—R 4 , R 4 —O(C═O)NH—, —(CH 2 ) b —(C═0)—(CH 2 ) c —R 4 , —NH—S(O) 2 —R 4 , —C(OH)R 4 R 5 , —CH(OH)—R 4 , —(C═O)—NR 4 R 5 , —CN, —NO 2 , substituted C 1 to C 6 alkyl, substituted or unsubstituted C 1 to C 6 alkenyl, or substituted or unsubstituted C 1 to C 6 alkynyl, said substituted moieties substituted with a moiety of the formulae —R 4 , —R 4 R 5 , —O—R 4 , or —S(O) d —R 4 . These compounds are useful psychotherapeutics and are potent serotonin (5-HT 1 ) agonists and antagonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotranmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  公式1的化合物，其中R1是公式2，R2是—R4，—O—R4，—O—S(O)2—R4，—NR4R5，R4—(CH2)b—NH(C═X)—(CH2)c—，R4—(CH2)b—O(C═O)NH—(CH2)c—(C═O)NH—，R4(C═O)NH—(C═O)NH—，—(CH2)b—NH(C═X)—(CH2)c—R4，R4—(CH2)b—O(C═)—(CH2)c—，—(CH2)b—O(C═O)—(CH2)c—R4，—NH(C═X)NH—R4，R4—O(C═O)O—，—O(C═)NH—R4，R4—O(C═O)NH—，—(CH2)b—(C═O)—(CH2)c—R4，—NH—S(O)2—R4，—C(OH)R4R5，—CH(OH)—R4，—(C═O)—NR4R5，—CN，—NO2，取代的C1至C6烷基，取代或未取代的C1至C6烯基，或取代或未取代的C1至C6炔基，所述取代基团被公式—R4，—R4R5，—O—R4或—S(O)d—R4的基团取代。这些化合物是有用的精神治疗剂，并且是强效的血清素（5-HT1）激动剂和拮抗剂，可用于治疗抑郁症、焦虑症、饮食失调、肥胖、药物滥用、丛集性头痛、偏头痛、疼痛和慢性阵发性偏头痛以及与血管疾病相关的头痛，以及其他由血清素神经传递不足引起的疾病。这些化合物还可用作中枢作用抗高血压药和血管扩张剂。
• Compositions containing sertraline and a 5-HT.sub.1D receptor agonist or
  申请人：Pfizer Inc.

  公开号：US05597826A1

  公开（公告）日：1997-01-28

  The present invention relates to novel compositions containing the serotonin selective re-uptake inhibitor (SSRI), preferably (1S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenam ine, and an agonist or antagonist of the serotonin 1 (5-HT.sub.1) receptor and to the use of such compositions for treating or preventing a condition selected from mood disorders, including depression, seasonal affective disorders and dysthmia, anxiety disorders including generalized anxiety disorder and panic disorder; agoraphobia, avoidant personality disorder; social phobia; obsessive compulsive disorder; post-traumatic stress disorder; memory disorders including dementia, amnestic disorders and age-associated memory impairment; disorders of eating behavior, including anorexia nervosa and bulimia nervosa; obesity; cluster headache; migraine; pain; Alzheimer's disease; chronic paroxysmal hemicrania; headache associated with vascular disorders; Parkinson's disease, including dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias; endocrine disorders such as hyperprolactinaemia; vasospasm (particularly in the cerebral vasculature); hypertension; disorders in the gastrointestinal tract where changes in motility and secretion are involved; sexual dysfunction, including premature ejaculation; and chemical dependencies.

  本发明涉及包含选择性5-羟色胺再摄取抑制剂（SSRI），优选（1S-顺）-4-(3,4-二氯苯基)-1,2,3,4-四氢-N-甲基-1-萘胺，以及5-羟色胺1（5-HT1）受体的激动剂或拮抗剂的新组合物，以及使用这样的组合物治疗或预防情绪障碍，包括抑郁症、季节性情感障碍和情绪恶劣，焦虑障碍，包括广泛性焦虑障碍和恐慌障碍；恐旷症，回避性人格障碍；社交恐惧症；强迫症；创伤后应激障碍；记忆障碍，包括痴呆、遗忘障碍和与年龄相关的记忆减退；饮食行为障碍，包括厌食症和贪食症；肥胖；丛集性头痛；偏头痛；疼痛；阿尔茨海默病；慢性阵发性偏头痛；与血管疾病相关的头痛；帕金森病，包括帕金森病性痴呆、神经阻滞剂诱发的帕金森综合症和迟发性运动障碍；内分泌障碍，如高催乳素血症；血管痉挛（特别是在脑血管中）；高血压；涉及运动和分泌变化的胃肠道疾病；性功能障碍，包括早泄；以及化学依赖性。
• 5-arylindole derivatives
  申请人：Pfizer Inc.

  公开号：US05994352A1

  公开（公告）日：1999-11-30

  Compounds of the formula ##STR1## wherein A, B, D, E, and F are each independently nitrogen or carbon; R.sub.1 is hydrogen, C.sub.1 to C.sub.6 alkyl, --(CH.sub.2).sub.n R.sub.7, or C.sub.1 to C.sub.3 alkyl-aryl; R.sub.2, R.sub.3, R.sub.4, R.sub.5 and R.sub.6 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, aryl, C.sub.1 to C.sub.3 alkyl-aryl, halogen, cyano, nitro, --(CH.sub.2).sub.m NR.sub.8 R.sub.9, --(CH.sub.2).sub.m OR.sub.9, --SR.sub.9, --SO.sub.2 NR.sub.8 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9, --(CH.sub.2).sub.m NR.sub.8 COR.sub.9, --(CH.sub.2).sub.m CONR.sub.7 R.sub.9, or --(CH.sub.2).sub.m CO.sub.2 R.sub.9 ; R.sub.2 and R.sub.3, R.sub.3 and R.sub.4, R.sub.4 and R.sub.5, and R.sub.5 and R.sub.6 may be taken together to form a five- to seven-membered alkyl ring, a six-membered ary ring, a five- to seven-membered heteroalkyl ring, having 1 heteroatom of N, O, or S, or a five- to six-membered heteroaryl ring having 1 or 2 heteroatoms of N, O, or S; R.sub.7 is --OR.sub.10, --SR0.sub.10, --SO.sub.2 NR.sub.10 R.sub.11, --NR.sub.10 SO.sub.2 R.sub.11, --NR.sub.10 CO.sub.2 R.sub.11, --NR.sub.10 COR.sub.11, --CONR.sub.10 R.sub.11, or --CO.sub.2 R.sub.10 ; R.sub.8, R.sub.9, R.sub.10 and R.sub.11 are each independently hydrogen, C.sub.1 to C.sub.6 alkyl, or C.sub.1 to C.sub.3 alkyl-aryl; m is 0, 1, or 2; n is 2, 3, or 4; and the above aryl groups and the aryl moieties of the above alkyl-aryl groups are each independently phenyl or substituted phenyl, wherein said substituted phenyl may be substituted with one to three of C.sub.1 to C.sub.4 alkyl, halogen, hydroxy, cyano, carboxamido, nitro, or C.sub.1 to C.sub.4 alkoxy, and the pharmaceutically acceptable salts thereof. These compounds are useful in treating migraine and other disorders and are new. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and may be used in the treatment of depression, anxiety, eating disorders, obesity, drug abuse, cluster headache, migraine, pain, and chronic paroxysmal hemicrania and headache associated with vascular disorders, and other disorders arising from deficient serotonergic neurotransmission. The compounds can also be used as centrally acting antihypertensives and vasodilators.

  式为##STR1##的化合物，其中A、B、D、E和F分别独立地为氮或碳；R.sub.1为氢、C.sub.1到C.sub.6烷基、--(CH.sub.2).sub.n R.sub.7，或C.sub.1到C.sub.3烷基-芳基；R.sub.2、R.sub.3、R.sub.4、R.sub.5和R.sub.6分别独立地为氢、C.sub.1到C.sub.6烷基、芳基、C.sub.1到C.sub.3烷基-芳基、卤素、氰基、硝基、--(CH.sub.2).sub.m NR.sub.8 R.sub.9、--(CH.sub.2).sub.m OR.sub.9、--SR.sub.9、--SO.sub.2 NR.sub.8 R.sub.9、--(CH.sub.2).sub.m NR.sub.8 SO.sub.2 R.sub.9、--(CH.sub.2).sub.m NR.sub.8 CO.sub.2 R.sub.9、--(CH.sub.2).sub.m NR.sub.8 COR.sub.9、--(CH.sub.2).sub.m CONR.sub.7 R.sub.9，或--(CH.sub.2).sub.m CO.sub.2 R.sub.9；R.sub.2和R.sub.3、R.sub.3和R.sub.4、R.sub.4和R.sub.5，以及R.sub.5和R.sub.6可以结合在一起形成五至七元烷基环、六元芳环、具有1个N、O或S杂原子的五至七元杂烷基环，或具有1个或2个N、O或S杂原子的五至六元杂芳基环；R.sub.7为--OR.sub.10、--SR0.sub.10、--SO.sub.2 NR.sub.10 R.sub.11、--NR.sub.10 SO.sub.2 R.sub.11、--NR.sub.10 CO.sub.2 R.sub.11、--NR.sub.10 COR.sub.11、--CONR.sub.10 R.sub.11，或--CO.sub.2 R.sub.10；R.sub.8、R.sub.9、R.sub.10和R.sub.11分别独立地为氢、C.sub.1到C.sub.6烷基，或C.sub.1到C.sub.3烷基-芳基；m为0、1或2；n为2、3或4；上述芳基和上述烷基-芳基的芳基基团分别独立地为苯基或取代苯基，其中所述取代苯基可以用C.sub.1到C.sub.4烷基、卤素、羟基、氰基、羧酰胺基、硝基，或C.sub.1到C.sub.4烷氧基取代，并且其药学上可接受的盐。这些化合物在治疗偏头痛和其他疾病方面是有用的，并且是新的。这些化合物是有用的精神治疗药物，是有效的5-羟色胺（5-HT.sub.1）激动剂，可用于治疗抑郁症、焦虑症、进食障碍、肥胖症、药物滥用、集群头痛、偏头痛、疼痛，以及与血管疾病相关的慢性阵发性半头痛和头痛等疾病，以及由于5-羟色胺神经传导不足而引起的其他疾病。这些化合物还可用作中枢作用降压药和扩血管药。
• Spiro-hydantoin compounds useful as anti-inflammatory agents
  申请人：——

  公开号：US20040009998A1

  公开（公告）日：2004-01-15

  Compounds having the formula (I), and pharmaceutically-acceptable salts, hydrates, enantiomers, and diastereomers, and prodrugs thereof, 1 are useful as inhibitors of LFA-1/ICAM and as anti-inflammatory agents, wherein L and K are O or S; Z is N or CR 4b ; Ar is an optionally-substituted aryl or heteroaryl; G is a linker attached to T or M or is absent; J, M and T are selected to define a three to six membered saturated or partially unsaturated non-aromatic ring; and R 2 R 4a , R 4b , and R 4c are as defined in the specification.

  具有公式(I)的化合物，以及药用可接受的盐、水合物、对映异构体、非对映异构体和前药，可用作LFA-1/ICAM的抑制剂和作为抗炎剂，其中L和K是O或S；Z是N或CR4b；Ar是可选地取代的芳基或杂芳基；G是连接到T或M的连接剂或不存在；J、M和T被选用来定义一个三到六成员的饱和或部分不饱和的非芳香环；R2R4a, R4b, 和R4c如说明书所定义。
• Systematic Investigation of Resorcin[4]arene-Based Cavitands as Affinity Materials on Quartz Crystal Microbalances
  作者：Dimitrij Ryvlin、Oliver Dumele、Alexander Linke、Daniel Fankhauser、W. Bernd Schweizer、François Diederich、Siegfried R. Waldvogel

  DOI：10.1002/cplu.201700077

  日期：2017.3

  Resorcin[4]arene cavitands are well-known supramolecular hosts, and their outstanding guest-binding abilities in solution have been studied in detail in recent decades. In a systematic approach, different resorcin[4]arene cavitands and container molecules are characterized as affinity materials for gravimetric sensing using high-fundamental-frequency quartz crystal microbalances. Analysis of their

  间苯二酚[4]芳烃空洞体是众所周知的超分子宿主，近几十年来已经详细研究了它们在溶液中的杰出的客体结合能力。在一种系统的方法中，不同的间苯二酚[4]芳烃空洞和容器分子被表征为使用高基频石英晶体微量天平进行重量感测的亲和材料。对它们对一系列各种分析物的亲和力的分析表明，选择性和敏感性对腔体的形状，可及性和大小以及它们与宿主分子的超分子相互作用均具有显着依赖性。